A paper published this month in Lancet Diabetes and Endocrinology showed that disease-modifying therapies preserve beta cell function via C-peptide and also have beneficial metabolic effects in new onset type 1 diabetes (T1D). The paper included initial results from the Trial Outcome Markers Initiative (TOMI), which combined data from 21 disease-modifying therapy clinical trials. JDRF staff co-authored the paper, and JDRF has funded TOMI since it began.

“The results of this research underscore the value of collaboration and data-sharing across institutions, industry, and regulatory agencies to accelerate life-changing therapies for people with type 1 diabetes,” said Esther Latres, Ph.D., JDRF vice president of research. “Designing clinical trials for disease-modifying therapies in new-onset type 1 diabetes is challenging. This work will help address it.

There are many takeaways from this paper that will accelerate the clinical trial process for disease-modifying therapies. This includes the authors’ demonstrating that disease-modifying therapies that preserve beta cell function via C-peptide measurements also have beneficial metabolic effects.

JDRF is proud to have co-funded and been a part of this project, and we look forward to continuing our support.”

November 8, 2023